Celcuity Inc. (CELC) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $93.65. The rating moved from Neutral to Overbought on August 18, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$93.65
• Last changeMoved from Neutral to Overbought on August 18, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Celcuity Inc. sits in an attractive oncology-diagnostics thematic that is benefiting from stronger demand for improved screening and downstream biopsy/pathology services. Recent SEC filings and sector tailwinds (diagnostic product adoption, elevated M&A multiples) support potential upside, but limited publicly available financial detail and typical small-cap clinical/validation and reimbursement risks create material uncertainty. Near-term performance will hinge on validation readouts, partnership or commercial progress, and financing visibility; absent clearer financial disclosures, the stock is likely to remain sensitive to news flow and liquidity-driven swings.

Key factors

• Exposure to oncology diagnostic and screening tailwinds that are currently drawing investment and procedure volume.
• Two recent SEC filings flagged with positive sentiment, suggesting incremental corporate activity or disclosure progress.
• Sector-level readthroughs (diagnostics/AI-enabled navigation and demand for biopsy/pathology workflows) that can boost market demand for novel diagnostic assays.
• Elevated strategic M&A multiples in biotech which can create acquisition optionality or premium valuation for differentiated diagnostic assets.
• Calm near-term macro environment and balanced market risk appetite, which reduces short-term headline-driven volatility.

Risks

• Clinical or analytical validation results that fail to meet expectations, undermining commercial adoption.
• Payer/pricing pressure and payer strategic rationalization (MA plan pruning) that could limit reimbursement and revenue growth.
• Limited public filings available for detailed financial analysis, creating uncertainty around cash runway and potential dilution from future financings.
• Regulatory risk and long timelines for coverage/clinical guideline inclusion, slowing commercial traction.
• Low liquidity and small-cap volatility that can amplify share-price moves independent of fundamentals.
• Broader digital-health/privacy and FTC enforcement risks that could raise compliance costs or constrain partnerships in adjacent channels.

Latest MarketMoodz coverage

• Celcuity Expands Gedatolisib Program; Needham Sees Major Upside2026-05-15
• Celcuity Stock Rallies on VIKTORIA-1 Readout; FDA NDA Gets Priority Review2026-05-04
• eBay jumps ~8% in premarket on GameStop bid; 20 stocks move2026-05-04

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.